Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

Proceedings of the National Academy of Sciences of the United States of America

Volumn 99, Issue 16, 2002, Pages 10700-10705

  Roumiantsev, Sergei ^a   Shah, Neil P ^b   Gorre, Mercedes E ^b   Nicoll, John ^b   Brasher, Bradley B ^a   Sawyers, Charles L ^b   Van Etten, Richard A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HISTIDINE; IMATINIB; PHENYLALANINE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE ABL; UNCLASSIFIED DRUG;

ARTICLE; BLAST CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BINDING; ENZYME ACTIVE SITE; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SRC HOMOLOGY DOMAIN;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PHENYLALANINE; PHOSPHORYLATION; PIPERAZINES; POINT MUTATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TYROSINE;

EID: 0036678472     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.162140299     Document Type: Article

References (26)